Fresenius SE & Co. KGaA’s management board resolved to issue 13.8 million new ordinary shares with a total value of around 1 billion euros ($1.3 billion) to finance the planned acquisition of Rhoen-Klinikum AG (RHK), the company said in a statement.

The Else Kroener-Fresenius-Foundation, the company’s biggest shareholder, will buy at least 90 million euros of the new shares, according to the statement.

To contact the reporter on this story: Alex Webb in Frankfurt at awebb25@bloomberg.net

To contact the editor responsible for this story: Angela Cullen at acullen8@bloomberg.net